Lantern Pharma Inc
LTRN2.640USD
+0.080+3.13%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
29.15MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Lantern Pharma Inc Unternehmen
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Lantern Pharma Inc Informationen
BörsenkürzelLTRN
Name des UnternehmensLantern Pharma Inc
IPO-datumJun 11, 2020
CEOSharma (Panna L)
Anzahl der mitarbeiter24
WertpapierartOrdinary Share
GeschäftsjahresendeJun 11
Addresse1920 Mckinney Avenue
StadtDALLAS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl75201
Telefon19722771136
Websitehttps://www.lanternpharma.com/
BörsenkürzelLTRN
IPO-datumJun 11, 2020
CEOSharma (Panna L)
Führungskräfte von Lantern Pharma Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lee T. Schalop, M.D.
Dr. Lee T. Schalop, M.D.
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Bios Equity Partners, LP.
9.08%
Biological Mimetics, Inc
7.55%
Prophase Labs Inc
5.64%
The Vanguard Group, Inc.
3.43%
CM Management, LLC
2.01%
Andere
72.28%
Aktionäre
Aktionäre
Anteil
Bios Equity Partners, LP.
9.08%
Biological Mimetics, Inc
7.55%
Prophase Labs Inc
5.64%
The Vanguard Group, Inc.
3.43%
CM Management, LLC
2.01%
Andere
72.28%
Aktionärstypen
Aktionäre
Anteil
Corporation
13.19%
Venture Capital
9.08%
Investment Advisor
7.38%
Investment Advisor/Hedge Fund
2.08%
Hedge Fund
1.49%
Individual Investor
0.41%
Research Firm
0.09%
Andere
66.29%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
75
2.26M
20.24%
-397.59K
2025Q3
75
2.28M
21.15%
-484.54K
2025Q2
71
3.78M
35.06%
-589.53K
2025Q1
73
4.04M
37.50%
-292.34K
2024Q4
75
4.10M
38.06%
-404.66K
2024Q3
73
4.20M
39.03%
-539.55K
2024Q2
74
4.17M
38.76%
-357.16K
2024Q1
68
4.00M
36.90%
-906.94K
2023Q4
66
4.18M
38.50%
-1.07M
2023Q3
73
4.62M
42.50%
-2.30M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Bios Equity Partners, LP.
1.02M
9.08%
-60.24K
-5.60%
Sep 30, 2025
Biological Mimetics, Inc
844.13K
7.55%
--
--
Jul 23, 2025
Prophase Labs Inc
631.20K
5.64%
--
--
Jul 23, 2025
The Vanguard Group, Inc.
384.04K
3.43%
+20.32K
+5.59%
Sep 30, 2025
CM Management, LLC
225.00K
2.01%
+25.00K
+12.50%
Sep 30, 2025
Renaissance Technologies LLC
100.10K
0.9%
+9.50K
+10.49%
Sep 30, 2025
Geode Capital Management, L.L.C.
92.08K
0.82%
+190.00
+0.21%
Sep 30, 2025
Voss Capital LLC
50.00K
0.45%
--
--
Sep 30, 2025
GWM Advisors LLC
47.28K
0.42%
-9.23K
-16.33%
Sep 30, 2025
Keyser (Donald Jeffrey PH.D)
45.76K
0.41%
--
--
Jul 23, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Anteil0.01%
Avantis US Small Cap Equity ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
